Drug Delivery Deal Valuations
Executive Summary
In doing deals, large pharmaceutical companies have historically valued the underlying molecule higher than drug delivery mechanisms. But data on deal valuations show that the average valuation of drug delivery deals has jumped considerably over the last three years, with biotech-type deal terms such as large upfront, equity, and milestone payments.